用于治疗流感感染的氯硝柳胺制剂-猫眼课题宝

用于治疗流感感染的氯硝柳胺制剂

批准号：

10385194

负责人：

Gary Fujii

金额：

$29.85万

依托单位：

MOLECULAR EXPRESS, INC.

依托单位国家：

美国

项目类别：

财政年份：

2022

资助国家：

美国

项目状态：

已结题

起止时间：

2022-07-08 至 2023-06-30

来源：

https://reporter.nih.gov/project-details/10385194

关键词：

2019-nCoV A549 Adenoviruses Adverse reactions Aerosols Animals Anions Antiviral Agents Body Weight decreased Bronchoalveolar Lavage Cell physiology Cells Coronavirus Data Dengue Virus Disease Dose Drug Modelings Drug Screening Effectiveness Endosomes Enterovirus Evaluation FDA approved Female Formulation Goals Hela Cells Hepatitis C virus Human In Vitro Infection Influenza Influenza A Virus, H1N1 Subtype Influenza A virus Inner mitochondrial membrane Lead Lethal Dose 50 Lipids Liposomes Lung Middle East Respiratory Syndrome Coronavirus Modeling Molecular Monitor Morbidity - disease rate Mus Nasopharynx National Heart, Lung, and Blood Institute Neonatal Respiratory Distress Patients Pharmaceutical Preparations Phase Premature Infant Preparation Production Property Proteins Protons Pulmonary Surfactants Reporting Research Respiratory Disease Respiratory distress Rhinovirus SARS coronavirus Site Small Business Innovation Research Grant Standardization Technology Testing Time Viral Viral Load result Viral Respiratory Tract Infection Virus Virus Diseases Zika Virus absorption aerosolized anti-viral efficacy clinical application delivery vehicle improved influenza infection influenza virus strain influenza virus vaccine influenzavirus inhibitor lipid nanoparticle lipophilicity men&apos s group nanomolar novel pH gradient pandemic disease peptide B professor prophylactic public health relevance respiratory virus surfactant vaccine formulation

项目摘要

项目成果

Gary Fujii的其他基金

相似基金

相关文献

中文摘要

翻译

项目摘要该项目的主要目标是证明FDA批准的驱虫药，氯硝柳胺可以在合成的肺表面活性物质中重新配制，可以雾化治疗慢性阻塞性肺疾病由呼吸道病毒引起的感染。在此SBIR第一阶段应用中提出的研究将集中于在我们的专利肺表面活性物质中悬浮氯硝柳胺脂质体来检验这一概念技术(Niclosurf)和在小鼠流感挑战模型中测试候选Niclosurf配方。这个将评估Niclosurf作为流感引起的呼吸道病毒感染的治疗效果。

英文摘要

Project Summary The principal goal of this project is to demonstrate that the FDA-approved anthelminthic drug, niclosamide, can be reformulated in a synthetic lung surfactant which can be aerosolized for the treatment of infections caused by respiratory viruses. The studies proposed in this SBIR Phase I application will be focused on testing this concept by suspending niclosamide loaded liposomes in our proprietary lung surfactant technology (Niclosurf) and testing candidate Niclosurf formulations in a mouse influenza challenge model. The effectiveness of Niclosurf as a treatment for respiratory viral infections caused by influenza will be evaluated.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文